Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Andorra Health Watch.
Press releases published on July 2, 2025
PharmaTher Announces Path to Ketamine Commercialization with No Planned Financing, Confirms FDA Approval Goal Date of August 9th, 2025 for Ketamine
TORONTO, July 02, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company focused on the development and commercialization of ketamine-based pharmaceuticals, is …
Eyenovia Announces Rebranding and Corporate Name Change to Hyperion DeFi, Inc.
Name change reflects company’s leadership position with its cryptocurrency treasury reserve strategy focused on the HYPE token Company to commence trading on Nasdaq under the symbol “HYPD” effective July 3rd Also announces official launch of the Kinetiq x …
VYNE Therapeutics Provides Program Update on Oral BET inhibitor VYN202
BRIDGEWATER, N.J., July 02, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune- …
BriaCell Highlights Additional Phase 3 Clinical Sites Including Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven
Together, Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven add 30 satellite locations to enroll patients in BriaCell’s pivotal Phase 3 study BriaCell’s Phase 3 study currently has 58 active clinical sites across 15 states, including …
Abeona Therapeutics® Closes Sale of Rare Pediatric Disease Priority Review Voucher for $155 Million
CLEVELAND, July 02, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the closing of the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $155 million on June 27, 2025. Including net …
Beta Bionics to Announce Second Quarter 2025 Financial Results on July 29, 2025
IRVINE, Calif., July 02, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its second quarter 2025 financial results after …
Invivyd and Leading Researchers Form SPEAR (Spike Protein Elimination and Recovery) Study Group to Assess the Effects of Monoclonal Antibody Therapy for Long COVID and COVID-19 Post-Vaccination Syndrome
SPEAR Study Group initiated following multiple, independent reports of substantial clinical benefit associated with PEMGARDA® (pemivibart) therapy among people with Long COVID SPEAR Study Group collaborators Drs. Michael Peluso, Amy Proal, and David …
Dr. Oetker Takes the Stage with Suprema – A Sophisticated New Frozen Pizza Celebrated Through a Custom Opera Performance
TORONTO, July 02, 2025 (GLOBE NEWSWIRE) -- To mark its boldest product launch in over two decades, Dr. Oetker Canada is introducing Suprema not just as a premium frozen pizza, but as a work of art. As the centerpiece of a dynamic 360 campaign, Suprema …
Dr. Oetker monte sur scène avec Suprema, une nouvelle pizza surgelée sophistiquée célébrée par un spectacle d'opéra personnalisé
TORONTO, 02 juill. 2025 (GLOBE NEWSWIRE) -- Pour marquer le lancement de son produit le plus audacieux en plus de deux décennies, Dr. Oetker Canada présente Suprema non seulement comme une pizza surgelée de qualité supérieure, mais aussi comme une œuvre d …
Ligand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics
Pelthos plans to launch ZELSUVMI™ for the treatment of Molluscum contagiosum infections in July 2025 Concurrent with the closing of the merger, Ligand has invested $18 million in the combined company and is entitled to a 13% royalty on worldwide sales of …
Shattuck Labs Announces Participation in Upcoming Leerink Partners Therapeutics Forum: I&I and Metabolism
AUSTIN, TX and DURHAM, NC, July 02, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the …
Pelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private Placement
The combined company plans to launch ZELSUVMI™ for the treatment of molluscum contagiosum infections in July 2025 Concurrent with the closing of the merger, the combined company closed on a $50.1 million equity private placement Combined company will …
Tonix Pharmaceuticals Announces Peer-Reviewed Publication in Cancer Cell Journal Highlighting Positive Preclinical Data of mTNX-1700 in Gastric Cancer Animal Models
Combination treatment of mTNX-1700 (mTFF2-MSA fusion protein) with anti-PD1 antibody was associated with increased survival and decreased metastases in animal models of gastric cancer relative to anti-PD1 treatment alone mTNX-1700 treatment was associated …
ANI Pharmaceuticals to Participate at Leerink Partners Therapeutics Forum: I&I and Metabolism on July 8th
PRINCETON, N.J., July 02, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, will host 1x1 meetings at the Leerink Partners Therapeutics …
The Ensign Group Purchases Skilled Nursing Facility in Texas
SAN JUAN CAPISTRANO, Calif., July 02, 2025 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group of companies, which invest in and provide skilled nursing and senior living services, physical, occupational and …
Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors
US phase 1 trial of ‘2510 is expected to be initiated before the end of 2025 Anticipate ImmuneOnco sharing initial safety and efficacy results from phase 2 trial of ‘2510 + chemo in 1L NSCLC in the second half of 2025 DALLAS, July 02, 2025 (GLOBE NEWSWIRE) …
Ebenbuild Secures Euro 2.3 Million EIC Grant to Scale Digital Twin Platform for Respiratory Health
Funding supports market launch of platform for clinical and commercial applications Company targets Euro 15 billion in silico trials market and ICU decision support Munich, Germany – July 2, 2025 -- Ebenbuild, a company developing personalized, AI-enabled …
Belite Bio Announces Completion of Enrollment in the Pivotal Global Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant in Geographic Atrophy
- 500 subjects enrolled across the United States, the United Kingdom, France, Czech Republic, Switzerland, China, Taiwan, and Australia SAN DIEGO, July 02, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage drug development company …
OSE Immunotherapeutics met à jour l’information sur les procédures en cours
OSE Immunotherapeutics provides an update on ongoing proceedings NANTES, France, July 2, 2025, 8 AM – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) announces that following the hearing on June 24th, 2025, the President of the Nantes Commercial …